Gilead Sciences, Inc (GILD) FinancialsGILDFinancialGilead Sciences, Inc

Gilead Sciences, Inc. (GILD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Biktarvy, accounting for 48.3% of total sales, equivalent to $3.77B. Other significant revenue streams include Descovy and Trodelvy. Understanding this composition is critical for investors evaluating how GILD navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Gilead Sciences, Inc. maintains a gross margin of 79.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 32.76%, while the net margin is -134.51%. These profitability ratios, combined with a Return on Equity (ROE) of -20.57%, provide a clear picture of how effectively GILD converts its operational activities into shareholder value.

In the context of the broader market, GILD competes directly with industry leaders such as GMAB and AMGN. With a market capitalization of $171.56B, it holds a significant position in the sector. When comparing efficiency, GILD's gross margin of 79.76% stands against GMAB's 92.73% and AMGN's 72.64%. Such benchmarking helps identify whether Gilead Sciences, Inc. is trading at a premium or discount relative to its financial performance.

Gilead's total revenue for Q2 2026 was $7.803 billion, showing a solid performance despite a recent net income loss. The gross margin remains strong at 79.76%, indicating efficient cost management.